國藥科技股份(08156.HK)公佈年度業績 醫療用品業務快速發展 收入大增281%
格隆匯9月29日丨國藥科技股份(08156.HK)公告,截至2020年6月30日止年度,公司取得收入1.66億港元,同比增加281%,而本期間毛利4470萬港元,同比增加88%。
收入大幅增加乃由於公司推動製造及銷售個人防護裝備的新業務以及醫療裝置及供應品的供應鏈服務需求殷切所致。毛利增加乃由於新業務增長勢頭的貢獻所致。
於報告期間下半年,由於醫療裝置及供應品的供應鏈服務需求殷切,故互聯網+服務業務錄得穩定增長。在互聯網+服務業務中,解決方案服務及供應鏈服務分別錄得收入零港元及1.29億港元,較上一財政年度同期的總收入增加逾8.6倍。
於報告期間下半年,集團已發展有關製造及分銷個人防護裝備設備的新業務分部。於報告期間,個人防護裝備的收入為3210萬港元,並錄得毛利1590萬港元及毛利率49%。預期個人防護裝備所產生的收入將為未來年度的其中一個業務增長引擎。
此外,截至本公告日,短短半年內,集團已於內地及香港共建立完成八個無塵生產車間,擁有二十多條口罩生產線及實現大規模量產,獲得規模經濟效益。
公司表示,回顧今年,透過建立全新的業務部門為集團挖掘固有業務價值和創造新的商業機遇,期待未來在醫療用品領域保持勢態、擴大收益,並抓住彩票╱防偽上的龐大空間,為股東們帶來豐厚回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.